21 February 2018 in Laryngoscope Investigative Otolaryngology
Objective: Examine the relationship between depression and changes in smell or taste.Study Design: Cross‐sectional analysis of 2011–2012 and 2013–2014 National Health and Nutrition Examination Survey (NHANES).Methods: We examined 5,275 adults ≥40 years old who completed smell and taste questionnaires as well as a validated depression assessment instrument, the Patient Health Questionnaire (PHQ‐9). Analyses incorporated sampling weights to account for the complex sampling design and associations were analyzed using multivariate logistic regression adjusted for related demographics and socioeconomic data.Results: The prevalence of altered smell and taste was 23.0% (95% CI: 20.7–25.3%) and 11.9% (95% CI: 10.7–13.1%), respectively. Among those who met criteria for major depressive disorder, the prevalence of altered smell and taste was higher at 39.8% (95% CI: 33.4–46.1%) and 23.7% (95% CI: 18.7–28.7%), respectively. In a multivariate model adjusting for age, gender, education, major comorbidities, smoking history, heavy alcohol use, sinus disease, cold symptoms, and trauma history, adults ≥40 and <65 years old who reported alterations in smell (OR: 1.64, p = 0.004) and adults ≥40 years old who reported alterations in taste (OR: 1.77, p = 0.001) were more likely to meet criteria for major depressive disorder.Conclusion: There is a strong association between major depression and alterations in smell and taste among certain age groups in the general U.S. population. Primary care providers should screen for depression when patients report changes in smell or taste.Level of Evidence: 4.
7 June 2021 in Journal of Immigrant and Minority Health
25 October 2017 in The Laryngoscope
31 May 2017 in The Laryngoscope
23 January 2018 in International Forum of Allergy & Rhinology
29 July 2023 in The Laryngoscope
Objective: Temperature‐controlled radiofrequency neurolysis of the posterior nasal nerve (PNN) has been approved for use since 2020. This review synthesized the published data to assess its efficacy for treatment of chronic rhinitis.Data Sources: Pubmed/Medline, Embase, Scopus, Web of Science.Review Methods: A systematic search was conducted with no restrictions on publication years in April 2023. RCTs and prospective investigations that reported the reflective Total Nasal Symptom Score (rTNSS) outcome of radiofrequency neurolysis as a single procedure in chronic rhinitis patients were included. Pooled estimates for change in rTNSS from baseline at 3 months and responder rates (≥30% reduction in baseline rTNSS) at 3 and 6 months were obtained. Other outcomes, such as postnasal drip and cough scores, quality of life (QoL) measures, and adverse events were included for qualitative review.Results: Five studies were included in the systematic review, of which four were included in the meta‐analysis. A total of 284 participants underwent treatment. The pooled change in rTNSS score at 3 months was −4.28 (95% CI, −5.10 to −3.46). The pooled responder rate at 3 months was 77.11% (95% CI, 68.21%–86.01%) and at 6 months 80.80% (95% CI, 70.85%–90.76%). Postnasal drip and cough scores and QoL also improved significantly at follow up. A total of 36 adverse events were reported in 21 (7.4%) patients.Conclusions: The findings from this review suggest that temperature‐controlled radiofrequency neurolysis of the PNN is effective at treating chronic rhinitis symptoms and that it has an overall favorable safety profile. Laryngoscope, 134:507–516, 2024